Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic Cancer
An integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.
Read More
Belantamab Mafodotin Significantly Extends PFS vs Daratumumab in Myeloma
Dr Vogel on Updated OS Data for Frontline Camrelizumab Plus Rivoceranib in Unresectable HCC
Dr Ramalingam on Osimertinib Post-Chemoradiotherapy in Unresectable, Stage III, EGFR-Mutated NSCLC
First-Line Camrelizumab Plus Rivoceranib Maintains Survival Benefit in Unresectable HCC